FDA Balks At CIR Public-Private Partnership In FY 2017 Budget Request
This article was originally published in The Rose Sheet
Executive Summary
Based on its fiscal 2017 budget justification, FDA does not support a congressional proposal to formalize Cosmetic Ingredient Review safety assessments through a public-private partnership. The agency still intends to prepare a report on the subject, as directed by Senate and House appropriations committees, but characterizes the proposed framework as "inappropriate."